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Previous studies have demonstrated that a small subpopulation of
brain tumor cells share key characteristics with neural stem
progenitor cells in terms of phenotype and behavior. These find-
ings suggest that brain tumors might contain ‘‘cancer stem cells’’
that are critical for tumor growth. However, the molecular path-
ways governing such stem cell-like behavior remain largely elusive.
Our previous study suggests that the phosphatase and tensin
homologue deleted on chromosome 10 (PTEN) tumor suppressor
gene, one of the most frequently mutated genes in glioblastomas,
restricts neural stemprogenitor cell proliferation in vivo. In the
present study, we sought to determine the role of PTEN in long-
term maintenance of stem cell-like properties, cell cycle entry and
progression, and growth factor dependence and gene expression.
Our results demonstrate an enhanced self-renewal capacity and
G0-G1 cell cycle entry and decreased growth factor dependency of
Pten null neuralstem progenitor cells. Therefore, loss of PTEN
leads to cell physiological changes, which collectively are sufficient
to increase the pool of self-renewing neural stem cells and promote
their escape from the homeostatic mechanisms of proliferation
control.
tumor suppressor  conditional knockout mouse model 
growth factor dependency  brain tumor
The phosphatase and tensin homologue deleted on chromo-some 10 (PTEN) tumor suppressor gene was the first phos-
phatase identified to be frequently mutateddeleted somatically
in various human cancers, including glioblastoma multiforme
(1–3). In addition, germline mutations in the PTEN gene have
been associated with Cowden syndrome and related diseases in
which patients develop macrocephaly of the brain and hyper-
plastic lesions in multiple organs with increased risks of malig-
nant transformation (4, 5).
PTEN contains a sequence motif that is highly conserved in
the members of the protein tyrosine phosphatase family. PTEN
possesses phosphatase activity on phosphotyrosyl and phospho-
threonyl-containing substrates (3, 6) in vitro and on phosphati-
dylinositol (3–5) trisphosphate, a product of phosphatidylinositol
3-kinase, both in vitro and in vivo (7–11). PTEN-deficiency leads
to accumulation of PIP3 and activation of signaling molecules
that are critical in controlling cell size, cell migration, cell death,
cell proliferation, and differentiation, all of which are involved
in normal development and tumorigenesis (12).
We and other groups have used Cre-loxP technology to
conditionally delete Pten in different regions of the brain and at
different developmental stages (13–18). By crossing Pten con-
ditional knockout mice with the Nestin-Cre line, we generated
mutant mice with a substantially increased brain size and a
doubled brain weight (13), similar to macrocephalic phenotypes
found in humans with inherited PTEN mutations. Further
studies indicated that the enlarged brain resulted from increased
cell proliferation, decreased cell death, and enlarged cell size.
Because all neural cell types are thought to be derived from a
common stem cell, the neural stem cell, the overall size increase
of the mutant brain prompted us to study the neural stem cell
population. Our in vitro neurosphere culture analysis indicated
that there were more stem cells in the mutant brain. Moreover,
PTEN-deficient neural stemprogenitor cells have a greater
proliferation capacity, which is due, at least in part, to a
shortened cell cycle time (13).
One explanation for this phenomenon is that PTEN truly
controls the stem cell self-renewing state and Pten deletion
promotes neural stem cell self-renewal. In this case, we would
expect to see a persistence of sphere-forming activity and
maintenance of multilineage potential of Pten null neural stem
cells in a long-term culture. Alternatively, effects of Pten dele-
tion, seen both in vivo and in vitro, could have been due to
enhanced proliferation of progenitors that were more limited in
their differentiation potential. In this case, the number of Pten
null spheres should remain the same, yet the size of the spheres
should be greatly reduced. To distinguish between these two
possibilities, in the current study, we performed stringent serial
neurosphere passage experiments. Our results indicate that the
loss of PTEN results in a prolonged self-renewal of neural
stemprogenitor cells, without an appreciable change in their
capacity for multipotential differentiation, whereas cortical
stemprogenitor cells derived from WT animals had a limited
capacity for self-renewal and gradually lost their capacity to
produce neurons during the same culture period. Microarray
analysis revealed prominent dysregulation of cell cycle-related
genes in PTEN-deficient neurospheres. Furthermore, f low cy-
tometric analysis indicated that PTEN-deficiency mediates en-
hanced neural stemprogenitor cell self-renewal by promoting
exit from G0G1A, and entrance into the cell cycle, in addition
to the enhanced G1-S transition reported in ref. 11. Taken
together, these data suggest that the loss of PTEN confers an
increased self-renewal capacity to neural stemprogenitor cells,
a potentially important mechanism for brain tumorigenesis.
Results
PTEN Negatively Regulates Neural Stem Cell Self-Renewal in Vitro.To
directly compare the properties of mutant (MUT) and WT
stemprogenitors, we first examined the effect of PTEN defi-
ciency on embryonic day (E) 14.5 cortices, an age when Pten
deletion is just complete. Cells were subjected to serial stringent,
low-density passaging (Fig. 1A), and their ability to form neu-
rospheres was recorded after each passage. As shown in Fig. 1B,
although spheres from80% of the MUT animals were capable
Conflict of interest statement: No conflicts declared.
Abbreviations: En, embryonic dayn; MUT, mutant; PTEN, phosphatase and tensin homolog
deleted on chromosome 10.
‡M.G. and R.E. contributed equally to this work.
¶Present address: Division of Biology, California Institute of Technology, Pasadena,
CA 91125.
††To whom correspondence may be addressed. E-mail: hkornblum@mednet.ucla.edu or
hwu@mednet.ucla.edu.
© 2005 by The National Academy of Sciences of the USA
www.pnas.orgcgidoi10.1073pnas.0509939103 PNAS  January 3, 2006  vol. 103  no. 1  111–116
CE
LL
BI
O
LO
G
Y
of forming spheres for at least five passages (P5), only 20% of
the WT cultures could do the same, owing to a lack of sufficient
viable cells for reseeding.
To further explore the role of PTEN in neural stem
progenitor cell self-renewal, we quantified the number of
spheres produced during each passage. Pten deletion resulted in
a greater number of spheres, especially at passages 2, 3, and 4
(Fig. 1C). This result indicates that MUT cultures have a greater
percentage of sphere-forming cells at each passage after initial
plating, consistent with an increased self-renewal capacity. Be-
cause our neurosphere cultures were reseeded at a specific cell
density, the results shown in Fig. 1C underestimate the total
sphere-forming potential of MUT stem cells over time. To
account for this underestimation, we estimated the total sphere-
forming capacity (i.e., the number of spheres predicted if all cells
from an individual culture were reseeded). These calculations
demonstrate an exponential difference between MUT and WT
sphere-forming capacity (Fig. 5, which is published as supporting
information on the PNAS web site).
Pten Null Spheres Are Multipotent and Have Greater Proliferation
Capacity. Neural stem cells can undergo multilineage differenti-
ation and give rise to neurons, astrocytes, and oligodendrocytes
(19). To verify that the effects observed above are indeed on
neural stem cells, rather than committed progenitors, we eval-
uated the differentiation potential of WT and MUT spheres
after each passage. As shown in Fig. 1 D and E (see also Fig. 6,
which is published as supporting information on the PNAS web
site), MUT spheres were multipotent and retained a similar
capacity to produce neurons and glia throughout the experiment,
suggesting that self-renewal was maintained. In contrast, WT
spheres demonstrated a loss of neurogenic potential over time
with serial, low-density passages (Fig. 1D and E), consistent with
the findings by others that cortically derived progenitors become
more glial-restricted over time (20). These data indicate that
PTEN loss not only supports persistent self-renewal, but main-
tains multilineage cell differentiation potential, resulting in a
sustained neural stem cell-like state.
MUT spheres were significantly larger at all passages mea-
sured (Fig. 7, which is published as supporting information on
the PNAS web site), similar to our previous study (13). As the
passage number increased, the differences in sphere size became
more significant (Fig. 7). In those few cases in whichWT spheres
could be passaged beyond four times, the differences in sphere
size were quite striking (Fig. 7 Left). These data are consistent
with the notion that PTEN loss enhances neural stem
progenitor proliferation over multiple passages, although con-
comitant effects on cell survival and cell size (see below) could
account for some of the differences seen in neurosphere size.
Pten Null Neural StemProgenitor Cells Have Diminished Requirement
for Growth Factor Stimulation. In the neurosphere culture system,
neural stem cells undergo self-renewing cell divisions in basic
medium supplemented with FGF2. To further understand
PTEN controlled stem cell self-renewal, we conducted growth
curve analyses by supplementing neurosphere cultures with
different concentrations of FGF2. More neurospheres can be
generated from MUT cortices than those of WT, even at
suboptimal concentrations (Fig. 2A), indicating that MUT stem
progenitor cells are hypersensitive to FGF2 stimulation. Simi-
larly, MUT spheres are larger, even in the presence of 100-fold
less growth factor (0.1 ngml, Fig. 2B), although PTEN loss
alone did not render neural stemprogenitor cell growth factor-
independent. These results indicate that PTEN is a potent
Fig. 1. PTEN loss leads to greater and persistent self-renewal capacity. (A) A
schematic illustration of the serial neurosphere culture system. (B) Percent-
ages of WT and MUT sphere cultures that can be serially passaged. (C) Sphere
formation relative to WT sphere counts at each passage. (D) Histograms show
the neurogenic potential of WT (in blue) and MUT (in red) neurosphere
cultures. WT spheres demonstrated a loss of neurogenic potential over time
with serial, low-density passages. Filled bars, spheres with neuron; hatched
bars, spheres without neuron. (E) Representative images of the neurogenic
potential of control and mutant neurospheres, with propridium iodide stain-
ing in Left and TuJ1 immunostaining in Right. (Scale bar: 17 m.) A, GFAP
astrocytes; O, O4 oligodendrocytes; N, Tuj1 neurons.
Fig. 2. Pten null neurospheres are hypersensitive to growth factor stimula-
tion. Identical number of cells from WT and MUT E14.5 front brains were
seeded in neurosphere cultures with the indicated concentration of FGF2.
Neurosphere numbers (A) and size (B) were measured 7 days after initial
culture and presented as mean  SD.
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negative regulator of the FGFR signaling pathway and neural
stem cell self-renewal and proliferation. Furthermore, decreased
reliance on growth-factor signals, a hallmark of cancer cell
biology (21), might also be important for mobilizing stem cells
from the quiescent stage (see below).
PTEN Negatively Regulates Entry into Cell Cycle. Somatic stem cells
rapidly respond to stress, such as tissue damage, by generating
progenitors and terminally differentiated cell types to replenish
damaged areas. Concurrently, stem cells also generate additional
stem cells, via amplification, before returning to quiescence.
Although stem cell cell cycle entry and exit happen naturally in
vivo, little is known about the genes and molecular mechanisms
controlling this process.
Using a CFSE washout experiment, we previously demon-
strated that PTEN deficiency leads to an increased number of
cell divisions in neural stem cells (13). This observation
prompted us to assess whether PTEN plays an important role in
controlling exit from the G0G1A (quiescent) stage of the cell
cycle, and entry into the G1B and SG2M stages of the cell cycle
(seeMaterials andMethods). Using two-color flow cytometry, we
labeled DNA and RNA simultaneously within fresh, dissociated
brain (Fig. 3A Upper) and in cultured neurospheres (Fig. 3A
Lower) (22).
A significant fraction of WT cells, either from the E14
forebrains or derived from dissociated first passage of neuro-
sphere cultures, were in the quiescent G0G1A cell cycle stage
(Fig. 3A Left), consistent with previous studies (23). Pten null
brains or neurosphere cultures, however, contained significantly
fewer cells in the G0G1A cell cycle stage, as compared to their
age- and genetic background-matched littermates (Fig. 3A
Right). Fig. 3B Left presents results from all experiments per-
formed (*, statistically significant).
Our previous study suggests that PTEN negatively controls
cell growth or size (13). To investigate whether cell size control
is correlated with cell cycle regulation, especially exit from
quiescence and cell cycle entry, we measured relative cell size at
different cell cycle stages flow cytometrically by assessing for-
ward scattered light. All cycling cells (G1B, S, and G2M) from
WT E14 forebrain or neurosphere cultures had higher forward
scatter values than G0G1A cells, indicating that the G0G1A
cells were smaller (Fig. 3B Right, in red). Similar to our previous
report, cells from Pten null brain are, on average, bigger at every
phase of cell cycle (Fig. 3B Right, in blue), although at the
quiescent G0G1A cell cycle stage, the mean forward scatter
value measured for Pten null cells was not substantially different
from that of the WT (Fig. 3B, Right). This result suggests that
enhanced cell growth may push Pten null cells to enter the G1B
phase of the cell cycle, resulting in a decreased G0G1A cell
population. This finding is generally in agreement with the
notion that cell growth or size control is largely regulated at the
translational level (24).
PTEN Negatively Regulates Genes Involved in Cell Growth and Cell
Cycle Control. The data described above support the hypothesis
that loss of PTEN results in a greater self-renewal capacity of
neural stemprogenitor cells. To further examine potential
mechanisms of PTEN controlled neural stemprogenitor cell
proliferation, we undertook an unbiased approach by analyzing
the gene expression profiling of MUT and WT neurospheres.
We identified 257 genes that differ between MUT and WT
neurosphere cultures at a confidence level of P 0.001. We then
performed hierarchical clustering (25) of differentially ex-
pressed genes. As expected, the six arrays clustered into two
major groups according to the genotype (Fig. 4A). These dif-
ferentially expressed genes can be further clustered into two
major groups (marked by white boxes): genes that are up-
regulated in the MUT (upper box) and genes that down-
regulated in the MUT (lower box).
The most significantly up-regulated genes in theMUT spheres
were cell cycle- and DNA replication-related genes, such as
cyclin B1, cyclin B2, cyclin D1, cyclin E1, Ki-67, and DNA
primases. Other examples of genes found to be up-regulated in
MUT spheres include PBKTOPK and maternal embryonic
leucine zipper kinase, which have previously been identified by
our group as being enriched in neural progenitors (26). Exam-
ples of genes found to be up-regulated in WT spheres were
primarily related to cell differentiation and metabolism such as
doublecortin, glutamate receptor (AMPA2), GABA receptor,
and glutamate dehydrogenase.
To gain a more systematic understanding of the results of the
gene expression analysis, we used the National Institutes of
Health’s DAVID software to classify our results into Gene
Ontology categories (Fig. 4B, EASE P  0.5). This analysis
would help to identify biological processes that are significantly
different between MUT and control cells. Results from Gene
Ontology analysis identified a highly significant (P 2.7 1022,
EASE statistic) overrepresentation of genes involved in regula-
Fig. 3. Loss of PTEN leads to increased G0G1A to G1B cell cycle transition as
well as increased cell growth. (A) Flowcytometric analysis of cell cycle status in
primary cells from E14.5 cortices (Upper) and cells that have gone through one
generation of neurosphere culture (Lower). Left, WT; Right, MUT. N-butyrate
treated neurosphere cultures, which are arrested at the G1A to G1B transition,
were used to demarcate the line (vertical axes) between cells falling into the
G0G1A stage (quiescence, Lower Left) and cells which have entered the G1B
stage of the cell cycle (Lower Right). (B Left) A comparison of cell cycle profiles.
Statistic analysis for brain: G0G1A, P 0.05; G1B, P 0.08; SG2M, P 0.43;
neurosphere: G0G1A, P  0.05; G1B, P  0.72; SG2M, P  0.00003. *,
statistically significant. (Right) Cell size profiles at different cell cycle stages.
Data include all experiments conducted. For brain, WT, n 10; Mut, n 5; for
neurosphere, WT, n  11; Mut, n  7.
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tion of the cell cycle as a key theme in the suite of gene expression
of the knockout cultures, along with DNA replication, repair and
cytokinesis. A complete list of those differentially regulated
genes is shown in Tables 1 and 2, which are published as
supporting information on the PNAS web site.
Discussion
To escape normal tissue homeostasis, tumor cells must acquire
multiple genetic aberrations that collectively establish the ma-
lignant phenotype (21). For glioblastoma multiforme, this pro-
tracted process might encompass several years and requires brain
tumor cells to maintain self-renewal capacities over extended
periods. Previously, we and others have demonstrated that only
a fraction of brain tumor cells have the ability to self-renew and
to maintain brain tumor growth (27–29). Although these obser-
vations are now well documented, the molecular mechanisms
governing these stem cell-like capabilities in brain tumors remain
largely elusive (29). PTEN mutation is one of the most frequent
genetic alterations associated with glioblastoma multiforme
(30–32). Our previous study indicates that deletion of Pten in the
embryonic brain leads to increased neural stemprogenitor cell
proliferation (13). In the present study, we sought to determine
whether loss of PTEN in neuralstem progenitor cells promotes
the long-term maintenance of stem cell characteristics and the
mechanisms underlying this maintenance.
Loss of PTEN in neural progenitors confers on them a greater
capacity for persistent self-renewal. Although sphere forming
activity in WT neurosphere cultures diminishes over time,
consistent with previous studies (33), Pten neurosphere
cultures can be stably maintained, suggesting that loss of PTEN
is sufficient for the propagation of self-renewal properties.
Consistent with this hypothesis, Sinor et al. (34) recently dem-
onstrated that overexpression of Akt-1, a critical downstream
target of PTEN signaling, results in enhanced self-renewal of
cortical progenitor cells.
It is unknown at present whether deletion of PTEN would
result in a similar phenotype in progenitors derived from other
embryonic regions or from the subventricular zone derived from
adult brain. Differences in the molecular mechanisms of self-
renewal are clearly present in embryonic and fetal neural stem
cells. For example, Bmi-1, a polycomb transcription factor,
regulates neural stem cell self-renewal in vivo at postnatal, but
not prenatal, stages, probably because fetal neural stem cells do
not express the cell cycle inhibitory proteins that are regulated
by Bmi-1 in vivo (35).
PTEN-deficient neurospheres retained their neurogenic po-
tential, and we did not observe stem cell ‘‘exhaustion’’ in
PTEN-deficient neurospheres derived from the embryonic cor-
tex. These findings, taken together, indicate that a deletion of
PTEN truly enhances stem cell self-renewal, rather than simply
promoting the proliferation of committed progenitors or those
with a limited capacity to self-renew. These findings are seem-
ingly in contrast to those of Kippin et al. (36), who studied
P21 neurospheres derived from postnatal subventricular
Fig. 4. Gene expression analysis. (A) Microarray data can be classified into two major groups, genes that are up-regulated in Pten null neurosphere cultures
(upper box) and genes that are down-regulated in Pten null neurosphere cultures (lower box). (B) Gene Ontology analysis.
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zone. P21 is a regulator of the G1 to S cell cycle progression. The
neurospheres derived from adult animals rapidly exhausted their
capacity to produce new neurospheres upon passaging. It is
interesting to note, however, that neurospheres derived from
younger P21-deficient animals had a more prolonged period of
enhanced self-renewal than those derived from older animals.
In the adult, stem cells represent a relatively quiescent sub-
population, which can enter the cell cycle upon growth factor
stimulation to replenish specific cellular populations and then
exit the cycle to reside in their niche (G0 cell cycle state) (37).
However, given the importance of the G0 cell cycle state for stem
cell biology, little is known about the molecular mechanisms
governing its establishment and maintenance. Results from a
comprehensive screen of 6,000 gene deletion mutants in Sac-
charomyces cerevisae by Jorgensen et al. (38) revealed a close link
between cell growth and cell cycle commitment. Their study
suggests that, upon growth factor stimulation, cells grow to a
critical size before entering the cell cycle and that the cell size
increase, in turn, might be driven by an enhanced translational
capacity. Importantly, one of the mutants identified is sch9, an
ortholog of mammalian Akt, which also regulates longevity and
stress resistance (39). Several studies in flies (40), yeast (41), and
mammals (42) now suggest the existence of a similar link
between cell growth and cell cycle commitment. Our observa-
tion, that cycling cells differ in cell size between WT and Pten
null neural stemprogenitor cells but differ less in quiescent G0
cells, is in agreement with above-mentioned studies and indicates
that the PTEN-AKT-TOR pathway, by regulating protein syn-
thesis and cell growth, may play an important role in cell cycle
commitment.
The enhanced self-renewal capacity, cell cycle commitment,
and proliferation potential of Pten-deficient neurospheres are
reflected in their gene expression profile. The maternal embry-
onic leucine zipper kinase is enriched in embryonic and adult
neural stemprogenitor cells and is required for their self-
renewal capacity (43). Because maternal embryonic leucine
zipper kinase is not a direct target of the PTEN signaling
pathway (43), its up-regulation suggests an enrichment of cells
with self-renewal capacity in Pten-deficient neurospheres. Like-
wise, the strong expression of Ki-67, a widely usedmarker for cell
cycle commitment, as well as the up-regulation of various cyclins,
is in line with the enhanced proliferation potential of Pten null
neural stemprogenitor cells.
In summary, the loss of PTEN enhances G0 cell cycle exit and
self-renewal capacity and decreases growth factor dependence.
These mechanisms collectively might increase the available pool
of self-renewing cells that allow the accumulation of further
mutational events (44). PTEN loss may also promote tumor
progression by providing tumor initiating cells a self-renewal
mechanism. Further study of PTENs function in human brain
cancer stem cells, especially the G0-G1 cell cycle regulation, may
provide both mechanistic insights and targets for treatment of
glioblastoma multiforme.
Materials and Methods
Neurosphere Culture. Cortices were dissected from E14 embryos
in ice-cold buffer (15 mM HepesNaHCO325 mM glucose in
Hanks’ balanced salt solution-Ca2 and Mg2 free). After
removal of the meninges, tissues were incubated in dissection
buffer containing papain (Worthington) and DNase I (Worth-
ington) for 10 min at 37°C, quenched with Ovomucoid protease
inhibitor, and then dissociated with fire-polished Pasteur pi-
pettes into single-cell suspensions. Cells were then cultured at a
low density of 5 cells per l by using an established neurosphere
culturing system (45). The following supplements were added to
the Neurobasal media: 1:50 B27, 1:100 Pen-Strep, 2 mM L-
glutamine (all from GIBCOBRL), 2 gml heparin (Sigma),
and 20 ngml FGF2 (PeproTech). Cells were incubated at 37°C
in the presence of 5% CO2. Additional FGF2 was added every
third day, and cultures were passaged every 7–14 days, depending
on the size of the spheres. During each passage, spheres were
enzymatically and mechanically dissociated with 0.05% Trypsin-
EDTA and fire-polished glass pipettes and then reseeded at the
same density. For each animal and passage, cells were seeded in
three separate dishes and the number of neurospheres is calcu-
lated as mean  SD.
For growth factor-dependent assays, cells from MUT (n  3)
and WT (n  3) forebrains were resuspended at 10 cells per l
in Neurobasal medium (GIBCO) supplemented with B-27
(GIBCO), 2 mM L-glutamine in 24-well dishes, and FGF2 was
added daily at concentrations indicated. For determining neu-
rosphere number and diameter, neurospheres were plated onto
acid-treated, polyL-lysine (0.1 mgml) and laminin (25 gml,
Becton-Dickinson) coated glass coverslips (Carolina Biological
Supply). Ten random view fields per sample were taken within
20 min after plating. A minimum cutoff of 50 m diameter was
used in defining a neurosphere as spheres below this cutoff were
not reliably multipotent (unpublished observations).
Passage Efficiency. The time interval between each passage was
determined by the size of the spheres. Spheres were passaged
when diameters ranged between 75 and 150 m. A culture was
terminated when there were not enough cells to reseed a 10-ml
culture at a density of 5 cells per l. An entire experiment was
terminated when there was not at least one MUT and one
control in the group.
Sphere Counts, Diameter Measurements, and Multilineage Differen-
tiation. After plating an aliquot of spheres onto polyL-lysine-
coated coverslips, the number of spheres were counted and
calculated as per 1,000 cells originally plated. The relative sphere
count in Fig. 1C was first calculated as an average of sphere
counts at each passage, then presented as the fold difference
between MUT and WT (n  14). MCID software (Imaging
Research, St. Catherines, ON, Canada) was used to measure
neurosphere diameters.
To test the capacity for multilineage differentiation of neural
stemprogenitor cells, spheres were centrifuged, and media
containing FGF2 was replaced with differentiation media: Neu-
robasal, 1:50 B27, 1:50 L-glutamic acid, 0.5 mM L-glutamine, and
1:100 pen-strep. Aliquots of 20–100 spheres were plated on
polyL-lysine-coated (Sigma) coverslips (Fisher) in 24-well plates
and allowed to differentiate for 5–6 days before staining for
neurons (Tuj1, Berkeley Antibody; or MAP2, Chemicon), as-
trocytes (GFAP, DAKO), and oligodendroctyes (O4, Chemi-
con). Hoechst and propidium iodide were both used for nuclear
counter staining.
Cell Cycle Analysis.Dissection of E14.5 forebrains was performed
as described above. After dissociation, cells were either directly
subjected to flow cytometric analysis or plated in Neurobasal
medium (GIBCO) supplemented with B-27 (GIBCO) at 10 cells
per l for 7 days. FGF2 was added daily at 10 ngml. Neuro-
spheres were then dissociated in buffer containing papain
(Worthington) and DNaseI (Worthington) and subjected to cell
cycle analysis.
Freshly dissociated brain or neurospheres were stained for
DNA and RNA content by using 7-amino-actinomycin D
(7AAD) and pyronin Y, respectively. Cells were suspended in
0.5 ml of a nucleic acid staining solution staining buffer [0.15 M
NaCl in 0.1 M phosphate citrate buffer (Sigma), containing 5
mM EDTA (Sigma), 0.5% BSA (fraction V, Sigma), and 0.02%
saponin (Sigma)]. Five microliters of 1 mgml 7AAD (Sigma)
was then added to each tube to a final concentration of 10gml.
The cells were incubated at room temperature in 7AAD solution
for 20 min, then cooled on ice for at least 5 min before washing
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the cells with 1 ml of cold PBS, and then resuspended in 0.5 ml
of cold NASS buffer containing 10 gml actinomycin D
(Sigma). Cells were cooled on ice for 10 min before the addition
of 5 l of 0.1 mgml pyronin Y (PolyScience, Wilmington, Pa.),
and left on ice for a minimum of 10 additional min before
acquisition of flow cytometric data. This protocol was adapted
from Schmid et al. (22). All f low cytometry was done on a
Becton-Dickinson FACScalibur flow cytometer and analyzed by
using FLOWJO analysis software (Treestar).
Control experiments were performed in parallel, in which the
cell cycle inhibitory drug N-butyrate was added to the neuro-
sphere cultures. The position of the vertical axis in the DNA
RNAplots in Fig. 3 marks the division between theG1A andG1B
stages of the cell cycle and is determined by the N-butyrate-
treated cells, which are blocked at the G1A to G1B transition.
The horizontal axis marks the division between the G1B and S
phases of the cell cycle and marks the division between cells that
have 2NDNA content (G0, G1A, and G1B) and cells with greater
than 2N DNA content (S, G2, and M).
Microarray. Three independent replicate MUT embryos and
paired control littermates were cultured as neurospheres for 14
days. Cultures were pelleted and RNA was extracted by using
TRIzol reagent, and checked for quality with an Agilent 2100
Bioanalyzer. RNA from all samples was labeled with both cy3
and cy5 by using the Agilent low RNA input fluorescent linear
amplification kit as per the manufacturer’s instructions, and
labeling was confirmed with a Nanodrop Spectrophotometer.
Each paired knockout and wild-type replicate was hybridized
onto two Agilent Mouse Development Oligo arrays with dye-flip
for a total of six arrays. Feature extraction was performed with
Agilent feature extractor software by using default settings with
Lowess normalization and a standard error model to assign
probability of differential regulation. To generate a gene list
(Fig. 4), we selected those genes with P  0.001 in five of six
arrays. To generate a larger list for clustering and DAVIDEASE
analysis, we used P  0.01 in five of six arrays. Initial data
manipulation and analyses were performed in Microsoft EXCEL.
Clustering was performed with GENESPRING 6.0. Gene Ontology
analysis was performed by using DAVID and EASE software
available from the National Institute of Health (http:
apps1.niaid.nih.govdavid). For Fig. 4, we used the DAVID set to
level 5.
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